Biotech prodigy Laura Deming, known for her pioneering work in human longevity investment, announced her latest venture, Cradle Healthcare Co., which she’s been quietly building over the past three years. Deming, who started investing in longevity as a teenager, is now shifting gears to focus on one of the most controversial fields in healthcare: reversible cryonics.
Cradle Healthcare is working to develop technology that could potentially freeze individuals with serious illnesses and revive them when cures become available. Unlike other cryonics companies, which primarily focus on freezing, Deming’s startup is placing an equal emphasis on rewarming, with the goal of ensuring that both processes can be done without damaging the body.
“Reversible cryonics means creating procedures that can cryopreserve and rewarm with function,” says Deming, who at just 30 years old has already built a distinguished career in longevity research and investment. Cradle Healthcare is working on a new type of cooling and rewarming machine and experimenting with innovative cryoprotectant combinations in its lab. The company has raised $48 million in funding, although the investors remain undisclosed.
Deming believes that the stigma surrounding cryonics has hindered its advancement, but she’s confident Cradle is on the verge of breakthrough discoveries that could make this futuristic concept a reality.
